Results 191 to 200 of about 3,831 (231)
Some of the next articles are maybe not open access.
International Journal of Antimicrobial Agents, 2018
The activity of meropenem/vaborbactam was evaluated against 11 559 Enterobacteriaceae isolates, including 330 carbapenem-resistant phenotypes (CRE) and carbapenemase genotypes collected worldwide during 2015. Antimicrobial susceptibility testing for meropenem/vaborbactam (inhibitor at 8 mg/L) and comparators was performed by the reference broth ...
Michael D Huband +2 more
exaly +3 more sources
The activity of meropenem/vaborbactam was evaluated against 11 559 Enterobacteriaceae isolates, including 330 carbapenem-resistant phenotypes (CRE) and carbapenemase genotypes collected worldwide during 2015. Antimicrobial susceptibility testing for meropenem/vaborbactam (inhibitor at 8 mg/L) and comparators was performed by the reference broth ...
Michael D Huband +2 more
exaly +3 more sources
Antimicrobial Agents and Chemotherapy, 2018 Meropenem-vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae .
Mojgan Sabet +2 more
exaly +2 more sources
Antimicrobial Agents and Chemotherapy, 2017 We evaluated the activity of meropenem-vaborbactam against contemporary nonfastidious Gram-negative clinical isolates, including Enterobacteriaceae isolates with resistance phenotypes and carbapenemase genotypes.
Mariana Castanheira +2 more
exaly +2 more sources
An Update on Existing and Emerging Data for Meropenem-Vaborbactam
Clinical Therapeutics, 2020The search for new agents to treat multidrug-resistant gram-negative bacterial infections has been ongoing. Specifically, carbapenem-resistant Enterobacteriaceae (CRE) infections often exhibit multiple resistance mechanisms, including alterations in drug structure, bacterial efflux pumps, and drug permeability.
Bethany R, Shoulders +2 more
openaire +2 more sources
An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia
Expert Opinion on Pharmacotherapy, 2020Introduction: Nosocomial pneumonias are the second most common healthcare-associated infections (HCAIs), often associated with the presence of Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter species, and Enterobacter species.
Lauren M. Groft +2 more
openaire +2 more sources
Oxygenator impact on meropenem/vaborbactam in extracorporeal membrane oxygenation circuits
Perfusion, 2021Introduction: To determine the oxygenator impact on alterations of meropenem (MEM)/vaborbactam (VBR) in a contemporary neonatal/pediatric (1/4-inch) and adolescent/adult (3/8-inch) extra corporeal membrane oxygenation (ECMO) circuit including the Quadrox-i ®
Jeffrey J Cies +8 more
openaire +2 more sources
Antimicrobial Agents and Chemotherapy, 2017 Vaborbactam (formerly RPX7009) is a new β-lactamase inhibitor based on a cyclic boronic acid pharmacophore with potent inhibitory activity against K lebsiella p neumoniae
Dongxu Sun +2 more
exaly +2 more sources
Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection
Expert Opinion on Drug Metabolism & Toxicology, 2018Meropenem/vaborbactam (M/V) represents the first carbapenem and β-lactamase inhibitor combination approved for treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. Vaborbactam is a novel boronic acid, β-lactamase inhibitor with a high affinity for serine β-lactamases, including Klebsiella pneumoniae carbapenemase (KPC ...
Rodrigo M, Burgos +3 more
openaire +2 more sources